-
Oct 15, 2024 | 
healio.com | Victoria Langowska |Kristen Dowd |Marc E. Rothenberg
You've successfully added Food Allergy to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Native American patients were five times as likely to have a family history of atopic dermatitis.
-
Sep 6, 2024 | 
scienceblog.cincinnatichildrens.org | Marc E. Rothenberg |Kara Kliewer
For children with eosinophilic esophagitis (EoE)—a chronic immune disease typically triggered by food allergens—treatment often focuses on food elimination diets. Conventional therapy involves eliminating multiple food groups. However, new research from Cincinnati Children’s suggests that eliminating a single food may be just as effective.
-
Jun 26, 2024 | 
scienceblog.cincinnatichildrens.org | Marc E. Rothenberg |Margaret Collins |Julie M. Caldwell
Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn’t make patients feel better and doesn’t reverse tissue damage in their throats. Meanwhile, data shows that a different drug that had previously been approved for use in adults and teens with EoE is also safe and effective for children under 12 who weigh at least 15 kg (about 33 pounds).
-
Apr 1, 2024 | 
scienceblog.cincinnatichildrens.org | Marc E. Rothenberg
Eosinophils and mast cells are two of several types of white blood cells that are part of our normally protective immune system. Patients with eosinophilic gastrointestinal diseases (EGIDs)–a group of severe food allergy-related conditions–have abnormally high levels of eosinophils and mast cells in their digestive tract tissues. Eosinophils can promote excessive inflammation and tissue damage. Over the years, eosinophil counts have emerged as the key biomarker for tracking the severity of EGID.
-
Mar 11, 2024 | 
cincinnatichildrens.org | Marc E. Rothenberg
Cincinnati Children’s becomes the only NIH-funded clinical research center for food allergy in the region
Cincinnati Children’s has been awarded a grant through the National Institutes of Health (NIH) to join the Consortium of Food Allergy Research (CoFAR) as a clinical research center.
-
Feb 12, 2024 | 
healio.com | Richard Gawel |Marc E. Rothenberg |Scott H. Sicherer
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Healio compiled the most-read news in allergy, asthma and immunology posted in January.
-
Feb 5, 2024 | 
healio.com | Richard Gawel |Kristen Dowd |Marc E. Rothenberg |Woody Bryan
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients experienced significant improvements in dysphagia median symptom scores. Eosinophils and CD4+ and CD8+ cells all decreased, and regulatory T and B cells increased.
-
Jan 26, 2024 | 
scienceblog.cincinnatichildrens.org | Leah C. Kottyan |Matthew T Weirauch |Marc E. Rothenberg
Symptoms of eosinophilic esophagitis (EoE) mirror those of many common conditions, making it challenging to diagnose. Surgical biopsy is the diagnostic gold standard, but no guidelines exist to help clinicians decide whether to perform one. Researchers at Cincinnati Children’s hope to improve the way genetic risk can be incorporated into decision making with help from a novel, DNA-based tool called massively parallel reporter assays (MPRA).
-
Jan 26, 2024 | 
healio.com | Kristen Dowd |Marc E. Rothenberg |George D. Yancopoulos
Marc E. Rothenberg, MD, PhD The approval of dupilumab for children starting at age 1 year is an amazing advance for patients and families suffering from EoE. The scientific basis for using dupilumab for EoE is based in part by research conducted by my laboratory. I am grateful to the CURED Foundation and NIH and others for their long-term financial support, which provided critical funds that were leveraged for the basic research that led to this important advancement.
-
Jul 14, 2023 | 
pubmed.ncbi.nlm.nih.gov | Marc E. Rothenberg
